Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 09:15:13 AM Mon, 20 Apr 2020   Contact Information W. K. Alfred Yung Associated Profiles  Professor, Neuro-Oncology, Margaret and Ben Love Chair of Clinical Care, UT MD Anderson Cancer Center     1515 Holcombe Blvd., Box 0431        wyung@mdanderson.org     713-794-1285    Web Link    Neuro-Oncology, Glioma, Brain Tumors, Pre-Clinical Development, Astrocytoma, Glioblastoma Multiforme (GBM)    Associated Profiles Research and Expertise Affiliations Appointments  Research and Expertise Research Interests   For years, Dr. Yung and his team have been studying treatment options for patients with Glioblastoma multiforme (GBM) –the most deadly type of brain cancer – with an average 18-month lifespan after diagnosis. Dr. Yung is focused on drugs that target a gene called PI3K, which is a key factor in about 30% of GBM cases. His team collected glioma stem cells (GSCs) from GBM patients and developed a special panel of cell lines to investigate patterns of resistance to P13K inhibitors. The researchers are figuring out the molecular profile of these GSCs to identify potential targets for drug development. Results from the P13K studies have shown that the molecular profile of GSCs contain increased levels of Wee-1, which is a protein that controls cell division and growth. Following these results, the team then combined a P13K inhibitor with a Wee-1 inhibitor and found there was a greater inhibition of cell growth and the cancer cells were induced into cell suicide. Plus, when they tested the same inhibitors on complex GBM tumor models, they discovered similar benefits. These findings reveal molecular targets and designs for combination therapies that could lead to new treatments for GBM patients. Earlier in his career, Dr. Yung led the study that paved the way for FDA approval of temozolomide (Temodar®) for GBM and led the registration study that preceded FDA approval of the drug bevacizumab (Avastin®) for recurrent GBM.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Affiliations  Research Consortia John S. Dunn GCC for Chemical Genomics  Appointments Title Department / School Institution Professor Neuro-Oncology MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.